Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Real-world evidence has demonstrated improved glycemic control and insulin management following introduction of smart insulin pens in a Swedish type 1 diabetes (T1D) population. To understand the implications for healthcare costs and expected health outcomes, this analysis evaluated the long-term cost-effectiveness of introducing smart insulin pens to standard-of-care T1D treatment (standard care) from a Swedish societal perspective. METHODS: Clinical outcomes and healthcare costs (in 2018 Swedish krona, SEK) were projected over patients' lifetimes using the IQVIA CORE Diabetes Model to estimate cost-effectiveness. Clinical data and baseline characteristics for the simulated cohort were informed by population data and a prospective, noninterventional study of a smart insulin pen in a Swedish T1D population. This analysis captured direct and indirect costs, mortality, and the impact of diabetes-related complications on quality of life. RESULTS: Over patients' lifetimes, smart insulin pen use was associated with per-patient improvements in mean discounted life expectancy (+ 0.90 years) and quality-adjusted life expectancy (+ 1.15 quality-adjusted life-years), in addition to mean cost savings (direct, SEK 124,270; indirect, SEK 373,725), versus standard care. A lower frequency and delayed onset of complications drove projected improvements in quality-adjusted life expectancy and lower costs with smart insulin pens versus standard care. Overall, smart insulin pens were a dominant treatment option relative to standard care across all base-case and sensitivity analyses. CONCLUSIONS: Use of smart insulin pens was projected to improve clinical outcomes at lower costs relative to standard care in a Swedish T1D population and represents a good use of healthcare resources in Sweden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
DiMeglio, L. A., Evans-Molina, C., & Oram, R. A. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31320-5 · Cited by 1,561
Glycemic Control and Excess Mortality in Type 1 Diabetes
Lind, M., Svensson, A.-M., Kosiborod, M., Gudbjörnsdottir, S., Pivodic, A., Wedel, H., Dahlqvist, S., Clements, M., & Rosengren, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408214 · Cited by 964
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
The relationship of hemoglobin A1C to time-in-range in patients with diabetes
Vigersky, R. A., & McMahon, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0310 · Cited by 464
Thirty Years of Prospective Nationwide Incidence of Childhood Type 1 Diabetes
Berhan, Y., Waernbaum, I., Lind, T., Möllsten, A., Dahlquist, G., & for the Swedish Childhood Diabetes Study Group* (2011) · Diabetes · doi:10.2337/db10-0813 · Cited by 237
Adolfsson, P., Hartvig, N. V., Kaas, A., Møller, J. B., & Hellman, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0411 · Cited by 139
Self-citation
Cited by
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Danne, T. P. A., Joubert, M., Hartvig, N. V., Kaas, A., Knudsen, N. N., & Mader, J. K. (2024) · Diabetes Care · doi:10.2337/dc23-2176 · Cited by 42
Cranston, I., Jamdade, V., Liao, B., & Newson, R. S. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02478-1 · Cited by 37
Ekberg, N. R., Hartvig, N. V., Kaas, A., Møller, J. B., & Adolfsson, P. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221104142 · Cited by 36
Self-citationTillman, J. B., Beck, R. W., Polonsky, W. H., Calhoun, P., Mouse, T., Bailey, R., Jacoby, J., Nandan, R., Sheikh, F. N., & Malone, J. K. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae778 · Cited by 1
Metadata
- Authors
- Jendle, J., Ericsson, Å., Gundgaard, J., Møller, J. B., Valentine, W. J., & Hunt, B.
- Venue
- Diabetes Therapy
- Published
- 2020-12-11
- Volume
- 12
- Issue
- 1
- Pages
- 373-388
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- OpenAlex
- W3111036774
- Cited by
- 68
- References
- 8
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.1007/s13300-020-00980-1
- The paper
- Jendle, J., Ericsson, Å., Gundgaard, J., Møller, J. B., Valentine, W. J., & Hunt, B. (2021). Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-020-00980-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.